Clinical trial NCT05087758: Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers
Official title: An Open-Label Trial to Assess the Clinical Effectiveness of Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Foot
Lower Extremity Wound
Keywords: diabetic foot ulcer
placental membrane
lower extremity wound
decellularized placental membrane
Lead sponsor: LifeNet Health
Sponsor class: INDUSTRY
First posted: 2021-10-21
Enrollment: 108
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is a multicenter, randomized, controlled, open-label trial designed to evaluate the safety and efficacy of Matrion on the wound healing rate of diabetic foot ulcers.
Primary purpose: TREATMENT

Brief summary: In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.


Eligibility criteria: Inclusion Criteria:

To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:

1. Be male or female, between 21 and 80 years of age at the time of consent
2. For subjects with a diagnosis of Type I or Type II diabetes as defined by the American Diabetes Association, have been on a stable anti-diabetic treatment for at least 30 days before the baseline visit
3. Have a full-thickness wound of the lower extremity
4. Have a single target ulcer
5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and a depth less than or equal to 9 mm
6. Have a diabetic foot ulcer that has been present for at least 30 days with a Wagner Classification Grade 1 or 2:

   * Grade 1: superficial diabetic ulcer including the full skin thickness but not underlying tissue
   * Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia, without presence of abscess of osteomyelitis
7. Have an absence of infection based on Infectious Disease Society of America criteria
8. Have an adequate circulation to the affected lower extremity, defined as at least one these criteria:

   * Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg
   * Ankle-brachial index (ABI) greater than 0.75
   * At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries
9. Have the ability to comply with off-loading (if required for specific wound) and dressing change requirements
10. Have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and agree to abide by the study restrictions and return to the site for the required assessments
11. Have provided written authorization for use and disclosure of protected health information
12. Have a life expectancy of greater than 6 months

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

1. Be pregnant or lactating
2. Have a wound that decreased in size ≥50% between the Screening and Baseline Visits
3. Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit
4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior to screening
5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin B Sulfate, and/or Vancomycin
6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®
7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit
8. Need for any additional concomitant dressing material other than the ones approved for this study
9. Have clinical signs of an infection at the study ulcer site
10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walker or a total contact cast)
11. Have a known or suspected disease of the immune system
12. Have an active or untreated malignancy or active, uncontrolled connective tissue disease
13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 30 days before the baseline visit
14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement
15. Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb less than 4 weeks before the baseline visit
16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than three times the normal upper limit within 30 days prior to screening
17. Have evidence of active Charcot disease
18. Have undergone treatment with a living skin equivalent within the last 4 weeks before screening
19. Have ongoing evidence of peripheral vascular disease, including greater than one nonpalpable pulse on either foot
20. Have the presence of any condition that in the opinion of the investigator places the subject at undue risk or potentially jeopardizes the quality of the data to be generated

Primary outcomes:
measure: Wound Healing
timeFrame: 12 weeks
Secondary outcomes:
measure: Speed of Wound Closure
timeFrame: 12 weeks
measure: Wound Area
timeFrame: 12 weeks
measure: Infection
timeFrame: 12 weeks
measure: Reoccurrence
timeFrame: 6 months post termination visit
measure: Grafts Used
timeFrame: 12 weeks
measure: Incidence of Treatment Emergent Adverse Events
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Compass Medical Research Center, LLC
state: Arizona
city: Carmichael
country: United States
facility: Center for Clinical Research, INC
state: California
city: Fresno
country: United States
facility: Limb Preservation Platform, INC
state: California
city: San Diego
country: United States
facility: ILD Research Center
state: California
city: San Francisco
country: United States
facility: Center for Clinical Research, INC
state: California
city: Miami
country: United States
facility: Doctors Research Network
state: Florida
city: Albuquerque
country: United States
facility: Albuquerque Associated Podiatrists
state: New Mexico
city: Rocky Mount
country: United States
facility: Purvis-Moyer Foot and Ankle Center
state: North Carolina
Study officials:
References: